Journal
MOLECULES
Volume 23, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/molecules23020340
Keywords
diabetes; GPR40; AKRB1; PPAR gamma; GLUT-4
Funding
- Consejo Nacional de Ciencia y Tecnologia (CONACyT) [253814]
- CONACYT fellowship [378373]
Ask authors/readers for more resources
We have synthesized a small series of five 3-[4-arylmethoxy) phenyl] propanoic acids employing an easy and short synthetic pathway. The compounds were tested in vitro against a set of four protein targets identified as key elements in diabetes: G protein-coupled receptor 40 (GPR40), aldose reductase (AKR1B1), peroxisome proliferator-activated receptor gama (PPAR gamma) and solute carrier family 2 (facilitated glucose transporter), member 4 (GLUT-4). Compound 1 displayed an EC50 value of 0.075 mu M against GPR40 and was an AKR1B1 inhibitor, showing IC50 = 7.4 mu M. Compounds 2 and 3 act as slightly AKR1B1 inhibitors, potent GPR40 agonists and showed an increase of 2 to 4-times in the mRNA expression of PPAR gamma, as well as the GLUT-4 levels. Docking studies were conducted in order to explain the polypharmacological mode of action and the interaction binding mode of the most active molecules on these targets, showing several coincidences with co-crystal ligands. Compounds 1-3 were tested in vivo at an explorative 100 mg/kg dose, being 2 and 3 orally actives, reducing glucose levels in a non-insulin-dependent diabetes mice model. Compounds 2 and 3 displayed robust in vitro potency and in vivo efficacy, and could be considered as promising multitarget antidiabetic candidates. This is the first report of a single molecule with these four polypharmacological target action.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available